Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231287 | 0.92 | BACE1 (0.67) | BACE1LTB4R | |
| Trifluoroacetic Acid SCHEMBL4242602 | 0.89 | BACE1 (0.55) | BACE1LTB4RCMA1CTRCSLC13A5 | |
| Trifluoroacetic Acid SCHEMBL4243869 | 0.85 | BACE1 (0.42) | BACE1CMA1CTRC | |
| Trifluoroacetic Acid SCHEMBL4248393 | 0.83 | BACE1 (0.53) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL4245228 | 0.83 | BACE1 (0.56) | BACE1CMA1CTRCSLC13A5GRM2 | |
| SCHEMBL8239238 | 0.82 | BACE1 (0.62) | BACE1LTB4R | |
| Trifluoroacetic Acid SCHEMBL4242063 | 0.75 | KMT2A (0.49) | BACE1LTB4RCMA1CTRC | |
| Trifluoroacetic Acid SCHEMBL4247341 | 0.75 | BACE1 (0.48) | BACE1CMA1CTRCAVPR1B | |
| SCHEMBL8231282 | 0.75 | BACE1 (0.46) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL4245400 | 0.74 | BACE1 (0.51) | BACE1CMA1CTRCAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | claimed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1951680-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885LTB4R 3309/4885CMA1 4445/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885LTB4R 3309/4885CMA1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.